NCPDP Foundation Awards $100,000 Grant to UTHSC College of Pharmacy to Demonstrate Value of Physician/Pharmacist Collaboration Using PeCP
Share Article
Pharmacist eCare Plan (PeCP) Standard is Used Between Providers to Improve Coordination of Care and Patient Health Outcomes
NCPDP Foundation SCOTTSDALE, Ariz. (PRWEB) February 11, 2021 The NCPDP Foundation Board of Trustees, who govern the 501(c)(3) nonprofit charitable organization that is affiliated with NCPDP, has awarded a $100,000 grant to University of Tennessee Health Science Center (UTHSC) College of Pharmacy for a research project to demonstrate the clinical value of integrating the NCPDP/HL7 Pharmacist eCare Plan (PeCP) in pharmacy and medical software systems. The Pharmacist eCare Plan is used for exchange with the patient and their care team to document medication-related health concerns and goals, as well as the pharmacist’s assessments, planned ac
Search jobs 08-Feb-2021 “Rare Voices” Podcast Series Continues: Optime Care Further Explores Unique Perspectives of Exceptional People Reshaping Patient Experiences With Rare & Orphan Diseases
EARTH CITY, Mo. (BUSINESS WIRE) #rarediseases Optime Care, a nationally recognized pharmacy, specialty distributor and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, is pleased to announce that “Rare Voices” Podcast Series Season 2 will be available in February 2021. Hosted by Donovan Quill, president and CEO, Optime Care, the podcast uncovers insights from patient advocates, pharmaceutical innovators, leaders in insurance, physicians and caregivers who share their experience and insights about the rare and orphan patient experience.
You can also directly click here to check the
Check and download the notification for future reference.
As per the short notification released by Odisha Staff Selection Commission (OSSC), Commission will conduct the mains examination through Computer Based Recruitment Examination (CBRE). The mains exam for Primary Investigator Post-2015 is scheduled to be held on March 2, 2021. The candidates who are selected will be deployed as the Primary Investigator Post under the Director of Textile and Handloom.
The Commission will release the details including exam program, date of downloading Admit Card, Mock Test/Practice Test before the actual examination. The details will be released on the official website of OSSC.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
GALAXY Medical CENTAURI PEF System to be Displayed at AF Symposium Recorded Case Presentation
January 21, 2021 GMT
SAN CARLOS, Calif., Jan. 21, 2021 /PRNewswire/ Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that the proprietary CENTAURI™ System will be featured in a recorded case presentation on Sunday January 31st during the upcoming AF Symposium.
Ante Anić, EP Lab Director at University Hospital Split and the Primary Investigator of the ECLIPSE-AF study, will be presenting the case which was completed as part of the ECLIPSE-AF study. Dr. Anić said: “The Galaxy Medical CENTAURI System has performed extremely well during the first 32 cases we have completed at our center and we felt this was a unique opportunity to share our experience with the EP community.”
News Category Global Banking & Finance Reviews
Simplify Medical Announces First Implantation of its Cervical Artificial Disc in the U.S. Following 1-Level Approval from the FDA
Simplify Medical Announces First Implantation of its Cervical Artificial Disc in the U.S. Following 1-Level Approval from the FDA
SUNNYVALE, Calif., Dec. 16, 2020 Simplify Medical, Inc., a privately-held company focused on cervical spinal disc arthroplasty and developer of the Simplify
® Cervical Artificial Disc, today announced its first surgery following the recent FDA approval for 1-level use. The Simplify Disc is designed for MRI compatibility , physiologic motion, and anatomical height-matching, with the goals of improving patient outcomes and expanding treatment options for patients. The Simplify Disc achieved superiority to the fusion control on the trial’s composite primary endpoint (93.0% vs. 73.6%).